The New Wellness Underdogs: How MSMEs Are Rewriting the Rules
Amit Srivastava has over 25 years of experience in nutraceuticals and medical foods. He pioneered the world's first 'Curated Intelligence' platform for idea-to-commercialisation and has held leadership roles at Legacy Healthcare and Dr Reddy's Laboratories, where he drove innovations in clinical nutrition and functional foods. His career began at Primedsys Pte Ltd, advising life sciences companies across Asia.
A quiet but powerful transfer of power is taking place in the wellness industry and it is being led by the underdogs. In this fascinating conversation, Amit Srivastava, Founder & Chief Catalyst, Nutrify Today, discusses how nimble HealthTech and nutraceutical MSMEs are beating the legacy behemoths at their own game by putting the individual, not the “average consumer” at the centre of product design. He lays out what it really takes for these ventures to scale credibly, from AI-driven personalization and connected patient platforms, to the pressing need for “smart capital” and predictable regulatory pathways. At its core, this is a story about wellness finding its “scientific soul”—where ancient ingredients meet modern proof, trust replaces hype, and precision replaces guesswork.
How are small tech teams successfully personalising complex patient data?
Lean teams succeed because they have given up on the old "one size fits all" approach to health, and that single decision changes everything about how they operate. For decades, the industry built products for an imaginary average consumer, a person who does not actually exist. Small tech teams have flipped that logic. They start with the individual, their genetics, their gut microbiome, their lifestyle, their sleep patterns, their stress markers, and work backwards to design a solution that fits that one person. This is not a marketing gimmick; it is a fundamentally different product development philosophy.
What makes this possible is a combination of agility and technology. These teams can move quickly without the corporate red tape that slows down larger organisations. A legacy company might need six committee approvals to change a formulation; a lean team can iterate in a week. They use AI to rapidly sift through millions of data points, from published clinical studies and biomarker readings to wearable device data and individual dietary habits, and translate all of that raw information into personalized health plans that a consumer can actually follow.
Also Read: BNP Paribas Cardif to Buy 26 Percent Stake in IndiaFirst Life
Crucially, the best of these teams do not treat technology as a substitute for science. They combine scientific rigour, regulatory know-how and digital technology to deliver targeted nutrition solutions in a fraction of the time it takes a legacy company. They employ nutritionists and data scientists at the same table, they validate their algorithms against clinical outcomes, and they keep refining the model as more data flows in. The result is personalization that is credible, compliant and continuously improving, rather than a static product sitting on a shelf hoping to suit everyone and truly suiting no one.
How does rewriting the health benefits playbook help MSMEs build a more resilient business?
Small and medium businesses always suffer from a lack of two things: time and money. Every sick day, every energy dip on the shop floor, every senior employee managing an unmanaged lifestyle condition comes with a direct and calculable cost. However, most MSMEs still consider employee health to be an afterthought, a line item that will only be addressed when something goes wrong. To rewrite the playbook on health benefits is to turn that mindset on its head, to view good nutrition and preventive care as business basics, not bonuses doled out when the balance sheet allows.
The shift from reactive health care to proactive wellness is much more strategic than a benefit for an employer. It’s defending its most important asset, its people. In an MSME, teams are small and everyone bears disproportionate responsibility. If a 10-person team loses one key member to preventable illness for two weeks, that’s 10 percent of the company’s capacity gone. Larger corporations can take that hit; small businesses often cannot. Prevention is not soft spending in this context. It's risk management.
Science-based structured nutrition programs help to reduce sick days, operational disruption and create a far more productive and engaged workforce. They also alter the employer-employee relationship. More and more talented people are choosing workplaces that visibly invest in their wellbeing and MSMEs that cannot match corporate salaries can absolutely compete on genuine care. This builds a culture of resilience over time: healthier teams, lower attrition, fewer surprises, and a business that can withstand pressure because its people can. And that’s the real return on writing the playbook again, year after year after year.
Also Read: Juniper Green Energy to Open Rs 1,800 Crore IPO
How are HealthTech MSMEs reengineering the modern patient experience?
Patients today are a fascinating paradox. They are more interested in their health than any previous generation, tracking their steps, reading ingredient labels, researching supplements late into the night, and yet they are also deeply sceptical of vague marketing claims. They have been burned by miracle cures and celebrity endorsements, and they now want proof. They want to know what is in a product, why it works, who tested it and what the evidence says. This scepticism is not a problem for the industry; it is the single greatest opportunity HealthTech MSMEs have ever been handed.
The traditional patient journey is broken and fragmented. A person sees a doctor in one silo, buys supplements in another, gets diagnostic tests in a third, and no part of the system talks to the others.
HealthTech MSMEs are building connected digital networks specifically to patch this fragmentation.
Their platforms bring the clinician, the diagnostic data, the nutrition intervention and the follow-up into one continuous, transparent loop. The clinician sees what the patient is taking; the patient sees the science behind the recommendation; and progress is measured rather than assumed.
These platforms offer transparent, data-driven information for both clinicians and patients, which changes the relationship from blind trust to informed partnership. By blending scientific precision with transparent ingredient tracking, right down to sourcing, batch testing and clinical substantiation, these companies are making wellness a reliable everyday practice, not a shot in the dark. The modern patient no longer has to choose between hope and evidence. That is a profound reengineering of the experience, and it is being led not by giants, but by small, focused teams who understand that trust is the real product.
Why are agile medical MSMEs essential, and what funding do they need to scale?
Small and nimble businesses are essential because they are where real innovation actually happens. Large companies are extraordinary at scale, but scale comes with inertia. Typical product development cycles in big organisations stretch to eighteen months or longer, weighed down by internal processes, portfolio politics and an understandable reluctance to disturb existing revenue streams. Agile MSMEs bypass all of this. They spot an unmet clinical need, formulate, test and launch while a larger competitor is still scheduling its second review meeting. In a sector where science moves monthly, that speed is not a luxury, it is the entire game.
But here is the uncomfortable truth about scaling in this industry: it takes more than a plain vanilla bank loan. A working capital facility designed for a trading business simply does not fit a company that must fund clinical validation, stability studies, regulatory dossiers across multiple markets and pharma-grade manufacturing before meaningful revenue arrives. Traditional lenders see risk where they should see rigour, and many promising ventures stall not because the science failed, but because the capital was the wrong shape.
Also Read: FSSAI Suspends Rehaan Healthcare License Over Food Safety Issues
What these companies need is what I call "smart capital": investors who genuinely understand the costs of scientific testing, regulatory approvals and complex supply chains, and who bring more than money to the table. Smart capital opens doors to global regulatory pathways, contract manufacturers, distribution partners and scientific advisory networks. It gives founders the runway to do things properly, launching products globally without cutting corners on evidence or compliance. When agile innovation meets capital that respects the science, you get companies that scale credibly. That combination is what will define the next decade of this industry.
What real-world regulatory support do health startups need to balance capital and compliance?
Startups do not just need cash; they need to stop wasting precious time and money guessing their way through messy, confusing and constantly shifting regulations. Ask any nutraceutical or health-food founder where their sleepless nights come from, and compliance will rank alongside fundraising. Which claims are permissible? Which ingredient approvals apply in which market? What changes when you export? The rules differ across geographies, evolve without warning, and the cost of getting them wrong ranges from expensive relabelling to complete market withdrawal. For a small team, one regulatory misstep can be existential.
The real support the ecosystem must provide is structural, not sympathetic. Startups need access to pre-vetted compliance frameworks, essentially ready-made regulatory roadmaps built by experts who have already navigated these pathways, so a founder is not reinventing the wheel with every product. Increasingly, they also need AI tools that monitor global regulatory movements and predict changes before they happen, flagging that an ingredient is under review in a target market or that a claims regime is about to tighten. Regulation should function like weather forecasting for these businesses: you cannot control it, but you should never be surprised by it.
The economics of this are compelling. A startup that can plug straight into a clear compliance pathway saves enormous amounts of time and money, often months of consultant fees and trial-and-error, and can redirect that energy toward research, product quality and growth rather than legal paperwork. Balancing capital and compliance is not about choosing between the two. It is about making compliance so predictable and accessible that capital can flow to genuine innovation with confidence.
What does the new "scientific soul" of wellness look like as startups shift from plant powders to AI?
The wellness industry is finally moving beyond the era of simply grinding up herbs, putting them in capsules and making loose, unverifiable health claims. That model had a long run, but it also created the credibility crisis the industry now has to repair. The new era looks completely different, and I would describe its character as a scientific soul: traditional wisdom is not being discarded, it is being interrogated, validated and elevated by serious science. The question is no longer "has this herb been used for centuries?" but "what exactly does it do, at what dose, in which population, and can we prove it?"
Predictive AI sits at the heart of this shift. Modern computational platforms can model how thousands of ingredients interact at a molecular level, screening for synergies, contraindications and bioavailability challenges, before anyone ever sets foot in a laboratory. What once took years of trial-and-error formulation can now be narrowed to a handful of high-probability candidates in weeks. This does not replace clinical validation; it makes clinical validation sharper, cheaper and far more likely to succeed, because you are testing formulations that the science already favours.
The startups leading this movement are combining natural ingredients with hard evidence and rigorous, pharma-grade testing, stability data, standardised actives, clinical endpoints and honest labelling. They are moving the entire category away from a trial-and-error system toward precision wellness. And that is the most exciting part of this story: the underdogs are not just building better products, they are rebuilding trust in an entire industry. When ancient ingredients meet modern proof, wellness stops being a leap of faith and becomes what it always should have been, a science.